<DOC>
	<DOCNO>NCT02019329</DOCNO>
	<brief_summary>This randomize , double-blinded , placebo-controlled study investigate safety , tolerability , pharmacokinetics multiple dos RO5545965 administer orally psychiatrically stable patient schizophrenia receive risperidone .</brief_summary>
	<brief_title>A Study Safety , Tolerability Pharmacokientics RO5545965 Patients With Schizophrenia Risperidone</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Males female age &gt; /= 18 year &lt; /= 60 year Clinically stable , mild moderate schizophrenia On stable antipsychotic treatment last 6 month Generally healthy investigator 's opinion , base assessment medical history , physical examination , vital sign , electrocardiogram ( ECG ) , result hematology , clinical chemistry , urinalysis , serology , laboratory test Willingness hospitalize approximately 3 week BMI &gt; 18.5 kg/m2 &lt; 38 kg/m2 Use highly effective contraception define study protocol . Men must also donate sperm least 30 day last dose , woman pregnant breastfeed Treatment antiparkinson medication include anticholinergic drug Treatment depot antipsychotic medication within last three month prior screen Participation clinical trial investigational drug device &lt; 3 month prior screen Smokes 20 cigarette per day Current drug abuse ( exclude nicotine ) drug abuse within 3 month prior screen visit Any donation blood significant blood loss within three month prior first administration study drug Use prohibit medication ( include vitamin herbal remedy ) take within 14 day within 5 time elimination halflife medication ( whichever longer ) first study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>